Faisalabad: Director General Faisalabad Development Authority (FDA) Muhammad Asif Chaudhary said that FDA One Window Counter has provided relief to 492 applicants during last six months while 40 applications are currently under process in different sections.
Chairing a meeting, he reviewed the performance of One Window Counter, the Khidmat Markaz, e-Buz Punjab, and the progress of official action on applications received through other departmental channels.
Additional Director General FDA Qaiser Abas Rind, Directors Junaid Hassan Manj, Asma Mohsin, Sohail Maqsood Pannu, Yasir Ejaz Chattha, Afnan Saeed Sandhu, Deputy Director IT Abdullah Noor and other officers were also present in the meeting.
Speaking on the occasion, he said that 367 applications related to the Estate Management-I Directorate, 40 applications pertaining to Town Planning-I, 60 applications of Town Planning-II, and 25 applications concerning the Katchi Abadi had been processed.
The services provided to applicants included approval of commercial and residential building plans, property transfers, inheritance mutations, commercialization approvals for properties, issuance of ownership clearance certificates, town planning reports, No Objection Certificates (NOCs), matters relating to housing schemes and various other departmental services, he added.
Expressing satisfaction over the overall performance of One Window Counter, Director General FDA Muhammad Asif Chaudhary directed that the high standard of departmental services should be maintained and that modern reforms and information technology be utilized to the fullest extent to ensure prompt public service delivery.
He further instructed that the One Window Counter system be made even more efficient to provide citizens with fast, transparent, and high-quality services, emphasizing the continuous improvement of service delivery through modern technology.
He stressed that all public applications must be processed within the prescribed timelines, warning that negligence or unnecessary delays would not be tolerated under any circumstances.
He also directed the Additional Director General FDA to continue strict monitoring of departmental performance, conduct daily reviews of official work, ensure the immediate resolution of unnecessary delays, and take impartial disciplinary action against negligent staff to further strengthen public confidence in the authority.